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Abstract
Background: Long non-coding RNAs (lncRNAs) have emerged as biomarkers and important regulators of tumor
development and progression. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a novel
long non-coding RNA that acts as a potential biomarker and involves in development of multiple cancers. However,
the clinical significance and molecular mechanism of PANDAR in bladder cancer is still unknown. In this study, we
aimed to figure out the role of PANDAR in bladder cancer.
Methods: The relative expression level of lncRNA PANDAR was determined by Real-Time qPCR in a total of
55 patients with urothelial bladder cancer and in different bladder cancer cell lines. We inhibited PANDAR
expression by transfecting PANDAR specific siRNA and enhanced PANDAR expression by transfecting a
PANDAR expression vector (pcDNA3.1-PANDAR). Cell proliferation was determined by using both CCK-8
assay and Edu assay. Cell apoptosis was determined by using ELISA assay, Hoechst 33342 staining and
Flow cytometry. Cell migration was determined by using transwell assay. All experimental data from three
independent experiments were analyzed by χ2 test or Student’s t-test and results were expressed as
mean ± standard deviation.
Results: We found that PANDAR was significantly up-regulated in bladder cancer tissues compared with
paired-adjacent nontumorous tissues in a cohort of 55 bladder cancer patients. Moreover, increased
PANDAR expression was positively correlated with higher histological grade (P < 0.05) and advanced TNM
stage (P < 0.05). Further experiments demonstrated that inhibited cell proliferation/migration and induced
apoptosis by silencing PANDAR were also observed in bladder cancer cells. Furthermore, over expression
of PANDAR in bladder cancer cells promoted the proliferation/migration and suppressed apoptosis.
Conclusions: These findings demonstrate that PANDAR plays oncogenic roles in bladder cancer and PANDAR
may serve as a potential prognostic biomarker and therapeutic target of bladder cancer.
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Background
Bladder cancer is the ninth most common malignancy
worldwide [1]. About 151297 newly diagnosed bladder
cancer cases and 52395 bladder cancer deaths were
appeared in Europe in 2014 [2]. Although in the past
years there are some progresses in clinical treatment for
bladder cancer, the overall survival (OS) time of bladder
cancer patients has not been improved dramatically, and
the 5-year survival rate for patients with bladder cancer
remains at only 50–60 % [3–5]. Because the prognosis of
bladder cancer is closely related to the stage of disease at
diagnosis, novel diagnostic markers for early stage are
urgently needed [6–9].
The long non-coding RNAs (lncRNAs) are important
new members of the ncRNA family, which are longer
than 200 nucleotides [10]. The rapid development of
cancer genomics has highlighted the role of lncRNAs in
human cancers [11–13]. Recently more and more evi-
dences showed that lncRNAs play crucial regulatory
roles in diverse biological processes, such as transcrip-
tional regulation, cell growth and tumorigenesis [14, 15].
However, the clinical significance and molecular mech-
anism of lncRNAs in bladder cancer remain largely elu-
sive. PANDAR (promoter of CDKN1A antisense DNA
damage activated RNA) is a novel lncRNA that was lo-
calized at 6p21.2.
Hung et al. reported that lncRNA PANDAR was
induced in a p53-dependent manner and interacts with
the transcription factor NF-YA to limit the expression of
pro-apoptotic genes [16]. Recently, lncRNA PANDAR
originally was identified as biomarkers and was involved
in development of multiple cancers [17, 18]. However,
the biological function and underlying mechanism of
action of lncRNA PANDAR in bladder cancer is com-
pletely unknown.
In this study, we found that lncRNA PANDAR was
significantly up-regulated in bladder cancer tissue com-
pared with paired-adjacent nontumorous tissues in a
cohort of 55 bladder cancer patients. Furthermore, in-
creased PANDAR expression was positively correlated
with higher histological grade (P < 0.05) and advanced
TNM stage (P < 0.05). We demonstrated that silencing
PANDAR significantly inhibited proliferation/migration
and induced apoptosis of the bladder cancer cells. More-
over, over expression of PANDAR in bladder cancer cells
promoted the proliferation/migration and suppressed
apoptosis. Our data suggest that PANDAR was a power-
ful tumor biomarker, which highlighted its potential
clinical utility as a promising prognostic biomarker and
therapeutic target.
Results
LncRNA PANDAR was up-regulated in bladder cancer
tissues and positively correlated with higher histological
grade and advanced TNM stage
The relative expression level of lncRNA PANDAR was
determined by Real-Time qPCR in a total of 55 patients
with urothelial bladder cancer. The lncRNA PANDAR
expression fold change (bladder cancer tissue/matched
normal tissue) in each patient was indicated in Fig. 1a.
As shown in Fig. 1b, c, lncRNA PANDAR was up-
regulated in bladder cancer tissues compared to pair-
Fig. 1 The relative expression levels of PANDAR in bladder cancer tissues and bladder cancer cell lines. The relative expression levels of PANDAR
were detected using Real-Time qPCR. The heights of the columns in the chart represent the log2-transformed fold changes (bladder cancer tis-
sue/normal bladder tissue) in PANDAR expression in 55 patients with bladder cancer (a). PANDAR expression levels were higher in bladder cancer
tissues than that in pair-matched adjacent normal tissues (b and c). PANDAR expression was significantly higher in patients with a higher histo-
logical grade and advanced TNM stage (d and e). PANDAR was up-regulated in bladder cancer cell lines compared to normal urothelial cell line
SV-HUC-1 (f). Data are shown as mean ± SD
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matched adjacent normal tissues. Moreover, increased
PANDAR expression was positively correlated with
higher histological grade and advanced TNM stage
(Fig. 1d, e). These results demonstrated that lncRNA
PANDAR should play oncogenic roles in bladder cancer.
Respectively, clinicopathological features of patients and
statistical results are shown in Tables 1 and 2.
LncRNA PANDAR was up-regulated in bladder cancer cell
lines and specific siRNA down-regulated and pcDNA
up-regulated expression of lncRNA PANDAR
The relative expression level of PANDAR was deter-
mined by using Real-Time qPCR in different cell lines.
PANDAR was up-regulated in bladder cancer cell lines
compared to normal urothelial cell line SV-HUC-1
(Fig. 1f ). Bladder cancer cells were cultured and then we
inhibited PANDAR expression by transfecting PANDAR
specific siRNA and enhanced PANDAR expression by
transfecting a PANDAR expression vector (pcDNA3.1-
PANDAR). At 48 h after transfection, the related expres-
sion level of PANDAR was determined by qRT-PCR and
the results showed that the relative level of PANDAR in
bladder cancer cells was significantly down-regulated by
the PANDAR siRNA(Fig. 2a) and up-regulated by the
pcDNA3.1-PANDAR (Fig. 2b).
Silencing lncRNA PANDAR inhibited cell proliferation and
overexpressing lncRNA PANDAR promoted cell
proliferation
We further determined whether PANDAR promotes cell
proliferation in bladder cancer. Three different bladder
cancer cells were transfected with PANDAR siRNA or
negative control siRNA. In the same way, three different
bladder cancer cells were transfected with pcDNA3.1-
PANDAR or pcDNA3.1-NC and the cell proliferation
changes of bladder cells were determined using both
CCK-8 assay and Edu assay. Inhibited cell proliferation
by silencing PANDAR was observed in 5637 cells (Fig. 3a
and Fig. 4a, d), SW780 cells (Fig. 3b and Fig. 4b, d) and
T24 cells (Fig. 3c and Fig. 4c, d) as expected. Promoted
cell proliferation by overexpressing PANDAR was ob-
served in 5637 cells (Fig. 3d and Fig. 4e, h), SW780 cells
(Fig. 3e and Fig. 4f, h) and T24 cells (Fig. 3f and Fig. 4g, h)
as expected. These results confirmed that PANDAR
promotes cell proliferation in bladder cancer.
Silencing PANDAR induced cell apoptosis and
overexpressing PANDAR suppressed cell apoptosis
We further determined whether PANDAR suppresses
cell apoptosis in bladder cancer. Three different bladder
cancer cells were transfected with PANDAR siRNA or
negative control siRNA. In the same way, three different
bladder cancer cells were transfected with pcDNA3.1-
PANDAR or pcDNA3.1-NC and the cell apoptosis
changes of bladder cells were determined using ELISA
assay, Hoechst 33342 staining and Flow cytometry. In-
duced cell apoptosis by silencing PANDAR was observed
in 5637 cells, SW780 cells and T24 cells (Fig. 5a, c and
Fig. 6a, c) as expected. Suppressed cell apoptosis by
overexpressing PANDAR was observed in 5637 cells,
SW780 cells and T24 cells (Fig. 5b, d and Fig. 6b, d) as
expected. These results demonstrated that PANDAR
suppresses cell apoptosis in bladder cancer.
Table 1 Correlation between PANDAR expression and clinicopathological features of UCB patients
Parameters Total Group Total PANDAR expression P value
High Low
Gender Male 40 (73 %) 27 (49 %) 13 (24 %) 0.953
Female 15 (27 %) 10 (18 %) 5 (9 %)
Age (years) < 60 20 (36 %) 14 (25 %) 6 (11 %) 0.745
≥ 60 35 (64 %) 23 (42 %) 12 (22 %)
Tumor size (cm) < 3 cm 21 (38 %) 11 (20 %) 10 (18 %) 0.061
≥ 3 cm 34 (62 %) 26 (47 %) 8 (15 %)
Multiplicity Single 32 (58 %) 21 (38 %) 11 (20 %) 0.759
Multiple 23 (42 %) 16 (29 %) 7 (13 %)
Histological grade G1 23 (42 %) 11 (20 %) 12 (22 %) 0.010*
G2,G3 32 (58 %) 26 (47 %) 6 (11 %)
Tumor stage T T1,T2 38 (69 %) 22 (40 %) 16 (29 %) 0.027*
T3,T4 17 (31 %) 15 (27 %) 2 (4 %)
Lymph nodes metastasis NO 53 (96 %) 16 (31 %) 36 (65 %) 0.607
YES 2 (4 %) 1 (2 %) 1 (2 %)
*P < 0.05 was considered significant (Chi-square test between 2 groups)
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Table 2 Summary of clinicopathological features of tissues of bladder cancer
Pt No. Sex Age Stage Grade Pt No. Sex Age Stage Grade
1 M 66 T2bN0M0 H 29 M 58 T4aN0M0 H
2 M 53 T1N0M0 L 30 M 63 T2aN0M0 L
3 M 75 T2bN0M0 H 31 M 50 T2bN0M0 H
4 F 64 T1N0M0 L 32 M 73 T3bN0M0 H
5 M 58 T3aN0M0 H 33 F 62 T4aN0M0 H
6 M 65 T2bN0M0 H 34 M 41 T1N0M0 L
7 F 38 T3aN0M0 H 35 M 62 T4aN0M0 H
8 M 59 T2bN0M0 H 36 M 76 T2bN0M0 L
9 M 43 T3aN0M0 H 37 M 25 T1N0M0 L
10 F 64 T2bN0M0 H 38 F 74 T3aN0M0 H
11 M 69 T1N0M0 L 39 F 70 T1N0M0 L
12 M 72 T3aN0M0 H 40 M 59 T4N0M0 H
13 F 89 T1N0M0 L 41 F 72 T1N0M0 L
14 M 68 T2bN0M0 H 42 M 46 T1N0M0 L
15 F 63 T3aN0M0 H 43 M 63 T3aN0M0 H
16 M 63 T2bN0M0 H 44 M 86 T1N0M0 L
17 M 78 T2aN0M0 L 45 M 70 T2bN0M0 H
18 M 70 T2aN0M0 L 46 M 49 T1N0M0 L
19 F 41 T2aN0M0 L 47 M 61 T3aN0M0 H
20 M 59 T2bN0M0 H 48 M 53 T2aN0M0 L
21 F 73 T2aN0M0 L 49 M 73 T2bN1M0 H
22 M 67 T2bN0M0 H 50 M 47 T2aN0M0 L
23 F 61 T3aN0M0 H 51 M 77 T3aN0M0 H
24 F 51 T1N0M0 L 52 M 66 T1N0M0 L
25 M 58 T4aN3M0 H 53 F 74 T2bN0M0 H
26 M 63 T2aN0M0 L 54 F 60 T2aN0M0 H
27 M 57 T4aN0M0 H 55 M 68 T1N0M0 L
28 M 54 T2bN0M0 H
Pt No. patient number; M male; F female; Grade the World Health Organization 2004 classification; H high; L low; Stage the American Joint Committee on Cancer
TNM classification
Fig. 2 Effects of corresponding siRNA or pcDNA on PANDAR expression. The relative expression level was determined using real-time qPCR. The
PANDAR specific siRNA significantly down-regulated the expression level of PANDAR in 5637, SW780, and T24 cells (a). The PANDAR specific
pcDNA significantly up-regulated the expression level of PANDAR in 5637, SW780, and T24 cells (b). Data are indicated as mean ± SD
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Silencing lncRNA PANDAR inhibited cell proliferation
and overexpressing lncRNA PANDAR promoted cell
migration
We further determined whether PANDAR promotes
cell migration in bladder cancer. Three different blad-
der cancer cells were transfected with PANDAR siRNA
or negative control siRNA. In the same way, three
different bladder cancer cells were transfected with
pcDNA3.1-PANDAR or pcDNA3.1-NC and the cell
proliferation changes of bladder cells were determined
using transwell assay. Inhibited cell migration by silen-
cing PANDAR was observed in 5637, SW780 and T24
cells (Fig. 7a and c) as expected. Promoted cell migra-
tion by overexpressing PANDAR was observed in 5637,
Fig. 3 Effects of down-regulation or up-regulation of PANDAR on cell proliferation. Cell proliferation was determined by CCK-8 assay. Cell proliferation
inhibition was observed in bladder cancer 5637 cells (a), SW780 cells (b) and T24 cells (c). Cell proliferation promotion was observed in bladder cancer
5637 cells (d), SW780 cells (e) and T24 cells (f). Data are shown as mean ± SD
Fig. 4 Effects of down-regulation or up-regulation of PANDAR on cell proliferation. Cell proliferation was also determined by Edu assay. Cell
proliferation inhibition was observed in bladder cancer 5637 cells (a and d), SW780 cells (b and d) and T24 cells (c and d). Cell proliferation
promotion was observed in bladder cancer 5637 cells (e and h), SW780 cells (f and h) and T24 cells (g and h). Data are shown as mean ± SD
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SW780 and T24 cells (Fig. 7b and d) as expected. These
results demonstrated that PANDAR promotes cell mi-
gration in bladder cancer.
Discussion
Bladder cancer is one of the most common malignancies
in human populations [19]. Because at the early stage of
bladder cancer there are no specific symptoms for these
patents, most bladder cancers are found at advanced-
stage, when treatments are less effective [20, 21]. The
prognosis of bladder cancer remains quite poor, there-
fore, finding new prognostic biomarker and therapeutic
target has enormous potential to improve the clinical
strategies and outcomes of bladder cancer [22, 23].
The lncRNAs are important new members of the RNA
family, which are longer than 200 nucleotides and not
translated into a protein [24, 25]. Recently, numerous
pieces of evidences indicate that lncRNAs play a crucial
Fig. 5 Effects of down-regulation or up-regulation of PANDAR on cell apoptosis. Cell apoptosis was determined by both ELISA assay and Hoechst
33342 staining assay. Induced cell apoptosis by silencing PANDAR was observed in bladder cancer 5637 cells, SW780 cells and T24 cells (a, b and c).
Suppressed cell apoptosis by overexpressing PANDAR was observed in bladder cancer 5637 cells, SW780 cells and T24 cells (d, e and f). Data
are shown as mean ± SD
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Fig. 6 Effects of down-regulation or up-regulation of PANDAR on cell apoptosis. Cell apoptosis was also determined by flow cytometry analysis.
Induced cell apoptosis by silencing PANDAR was observed in bladder cancer 5637 cells, SW780 cells and T24 cells (a and c). Suppressed cell apoptosis
by overexpressing PANDAR was observed in bladder cancer 5637 cells, SW780 cells and T24 cells (b and d). Data are shown as mean ± SD
Fig. 7 Effects of down-regulation or up-regulation of PANDAR on cell migration. Cell migration was determined by transwell assay. Inhibited cell
migration by silencing PANDAR was observed in 5637, SW780 and T24 cells (a and c). Promoted cell migration by overexpressing PANDAR was
observed in 5637, SW780 and T24 cells (b and d). Data are shown as mean ± SD
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role in cancer occurrence and progression [26, 27]. As a
new indentified lncRNA localized at the chromosome 6,
PANDAR is 1506 nucleotides in length [28]. LncRNA
PANDAR was previously reported to be up-regulated in
gastric cancer. PANDAR interacts with polycomb re-
pressive complexes (PRC1 and PRC2) and the transcrip-
tion factor NF-YA to repress the transcription of
senescence-promoting genes in cancer cells. However,
we know nothing about the relationship between
lncRNA PANDAR and bladder cancer.
To our knowledge, this is the first report of lncRNA
PANDAR being involved in the development of bladder
cancer. In the present study, we found that lncRNA
PANDAR was significantly up-regulated in bladder cancer
tissues than that in corresponding non-tumor bladder
tissues. These results suggest that lncRNA PANDAR may
emerge as a novel player in the state of bladder cancer. In
order to understand the biological functions of lncRNA
PANDAR, we detected the cell proliferation, apoptosis
and migration by silencing and overexpressing lncRNA
PANDAR in the related bladder cancer cell lines. Inhib-
ited cell proliferation/migration and induced cell apop-
tosis by silencing PANDAR were observed in bladder
cancer cells. Furthermore, overexpressing lncRNA PAN-
DAR promoted proliferation/migration and suppressed
apoptosis of the bladder cancer cells. These findings dem-
onstrate that lncRNA PANDAR may play key roles in the
progression and development in bladder cancer.
Conclusions
In conclusion, the expression level of the lncRNA PAN-
DAR is increased in bladder cancer tissues compared
with paired-adjacent nontumorous tissues. Increased
PANDAR expression has been associated with poor
prognosis, likely due to the ability of PANDAR to pro-
mote cell growth and metastasis in bladder cancer cells.
Cumulatively, these findings demonstrate that PANDAR
plays oncogenic roles in bladder cancer and PANDAR
may serve as a potential prognostic biomarker and
therapeutic target of bladder cancer.
Methods
Patients and clinical samples collection
A total of 55 patients with urothelial carcinoma of the
bladder who received partial or radical cystectomy were
included in this study. Bladder cancer tissue and
matched normal bladder tissue from each patient were
snap-frozen in liquid nitrogen immediately after resec-
tion. Written informed consent was also obtained from
all the patients. The study was approved by the Insti-
tutional Review Board of Shenzhen Second People’s
Hospital, Shenzhen, China and Peking University First
Hospital, Beijing, China.
Cell lines and cell culture
Bladder cancer 5637, SW780, UMUC3, T24 and SV-
HUC-1 cells used in this study were purchased from the
Institute of Cell Research, Chinese Academy of Sciences,
Shanghai, China. The 5637 cells and SW780 cells were
cultured in RPMI-1640 Medium (Invitrogen, Carlsbad,
CA, USA) plus 10 % fetal bovine serum. The UMUC3,
T24 and SV-HUC-1 cells were cultured in Dulbecco’s
Modified Eagle Medium (Invitrogen, Carlsbad, CA,
USA) plus 10 % fetal bovine serum. Plates were then
placed at 37 °C with an humidified atmosphere of 5 %
CO2 in incubator.
siRNA and pcDNA transfection
The specific small interfering RNA that targeted PAN-
DAR (si-PANDAR) and a scrambled negative control (si-
NC) were purchased from GenePharma, Shanghai, China.
The expression vector (pcDNA) that express PANDAR
(pcDNA-PANDAR) and a scrambled negative control
(pcDNA-NC) were also purchased from GenePharma,
Shanghai, China. The target sequence of si-PANDAR was
5′- GCAATCTACAACCTGTCTT -3′. The cells were
cultured 24 h prior to transfection. Then, the cells were
transiently transfected with corresponding si-RNA or
pcDNA using Lipofectamine 2000 Transfection Reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. After 48 h, cells transfected with
siRNA or pcDNA were harvested for qRT-PCR.
RNA extraction and quantitative real-time PCR
The total RNA of the tissue samples or the transfected
cells were extracted using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the instructions. The
concentration and purity of the total RNA were analyzed
with UV spectrophotometer analysis at 260 nm and the
electrophoresis detection showed good quality of puri-
fied RNA. cDNA was converted from total RNA by
using SuperScript III® (Invitrogen) according to the man-
ufacturer’s protocol. The primer sequences were as fol-
lows: PANDAR primers [8] forward: 5′- CTGTTAAGG
TGGTGGCATTG -3′, reverse: 5′- GGAGGCTCATA
CTGGCTGAT -3′; GAPDH primers forward: 5′- CG
CTCTCTGCTCCTCCTGTTC -3′, reverse: 5′- ATCC
GTTGACTCCGACCTTCAC -3′. Quantitative real-time
PCR was performed by using the ABI PRISM 7000
Fluorescent Quantitative PCR System (Applied Biosys-
tems, Foster City, CA, USA) according to the instructions.
The average value in each triplicate was used to calculate
the relative amount of PANDAR using 2^−ΔΔCt methods.
Experiments were repeated at least three times.
Cell counting Kit-8 assay
Cell proliferation was determined using Cell Counting
Kit-8 (Beyotime Inst Biotech, China) according to
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instructions. Briefly, 5 × 103 cells/well were seeded in a
96-well flat-bottomed plate for 24 h, then transfected
with corresponding si-RNA or pc-DNA and cultured in
normal medium. At 0, 24, 48 and 72 h after transfection,
10 μl of CCK-8 (5 mg/ml) was added to each well and
the cells were cultured for 1 h then determined the
absorbance at a wavelength of 450 nm using an micro-
plate reader (Bio-Rad, Hercules, CA, USA). Experiments
were repeated at least three times.
Ethynyl-2-deoxyuridine (EdU) incorporation assay
Cell proliferation was also determined by Ethynyl-2-
deoxyuridine incorporation assay using an EdU Apollo
DNA in vitro kit (RIBOBIO,Guangzhou, China) fol-
lowing the manufacturer’s instructions. Briefly, cells were
incubated with 100 μl of 50 μM EdU per well for 2 h at
37 °C, at 48 h after transfected with corresponding si-
RNA or pc-DNA, respectively. Then, the cells were fixed
for 30 min at room temperature using 100 μl of fixing
buffer (4 % polyformaldehyde containing PBS). Subse-
quently, the cells were incubated with 50 μl of 2 mg/ml
glycine for 5 min followed by washing with 100 μl of
PBS. After permeabilization with 0.5 % TritonX, the cells
were reacted with 1X Apollo solution for 30 min at
room temperature in the dark. After that, cells were in-
cubated with 100 μl of 1X Hoechst 33342 solution for
30 min at room temperature in the dark followed by
washing with 100 μl of PBS. The cells were then visual-
ized under a fluorescence microscopy. Experiments were
repeated at least three times.
Cleaved Caspase-3 ELISA assay
Cell apoptosis was determined by ELISA assay. Briefly,
5 × 105 cells/well were seeded in a 6-well plate for 24 h,
then transfected with corresponding si-RNA or pc-
DNA, respectively. At 48 h after transfection, Cell
cleaved caspase-3 activity was measured using the
Caspase-3 Colorimetric Assay kit (Abcam, Cambridge,
UK) according to the manufacturer’s protocol. Experi-
ments were repeated at least three times in duplicates.
Hoechst 33342 staining assay
Cell apoptosis was also determined by Hoechst 33258
staining assay. At 48 h after transfection with cor-
responding si-RNA or pc-DNA, apoptotic cells were
also observed by using the Hoechst 33258 staining kit
(Life, Eugene, OR, USA) according to the manufac-
turer’s instructions. Experiments were repeated at
least three times.
Flow cytometry analysis of cell apoptosis
Cells were cultured in normal medium and transfected
with corresponding si-RNA or pc-DNA. Cells were col-
lected after transfection for 48 h, and the translocation
of phosphatidylserine in treated cells was detected using
the Annexin-V-FLUOS staining kit (Roche Applied Sci-
ence, Mannheim, Germany). Briefly, after being labeled
with 5 μl of annexin V-FITC and 2 μl propidium iodide
(PI), cells were suspended in 500 μl of binding buffer
and incubated at room temperature in the dark for
15 min. Cell apoptosis was then determined by using
flow cytometry (EPICS, XL-4, Beckman, CA, USA). Ex-
periments were repeated at least three times.
Transwell assay
The cell motility assay were also performed using a
transwell insert (8 μm, Corning). Cells were cultured in
normal medium and transfected with corresponding si-
RNA or pc-DNA. 24 h after transfection, 5x104 cells
were first starved in 200 ml serumfree medium and then
placed in the uncoated dishes. The lower chamber was
filled with 500 ml of complete medium. The cells were
incubated for 48 h at 37 °C, and then the cells that had
migrated to the bottom surface of the filter membrane
were stained with 0.5 % crystal violet solution and
photographed in five preset fields per insert. Then the
absorbance were determined at a wavelength of 570 nm
using an microplate reader (Bio-Rad, Hercules, CA,
USA). The results represented the average of three inde-
pendent experiments.
Statistical analyses
All experimental data from three independent experi-
ments were analyzed by χ2 test or Student’s t-test and
results were expressed as mean ± standard deviation.
P-values of less than 0.05 were considered to be sta-
tistically significant. All statistical tests were con-
ducted by SPSS version 19.0 software (SPSS Inc.
Chicago, IL, USA).
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